BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for its brownfield expansion, known as Line II. This expansion includes a pre-filled syringes line, a liquid and lyophilized line, and a product development section.

Additionally, BF Biosciences Limited’s listing application has been approved by the Securities and Exchange Commission of Pakistan (SECP) and the Pakistan Stock Exchange (PSX), further strengthening its position in the pharmaceutical industry.

The company has commenced commercial production from the pre-filled syringes line, while the liquid and lyophilized line is undergoing internal validation and is expected to start commercial production in the second quarter of FY 2024-25.

In a significant development for diabetes management in Pakistan, BF Biosciences Limited has launched Sematide (Semaglutide) in a pre-filled syringe format. Sematide is the first Glucagon-Like Peptide 1 (GLP1) receptor agonist approved for local manufacture in Pakistan, offering a convenient solution for diabetes management. The pre-filled syringe format is designed to eliminate dosing errors and is user-friendly for patients. This product is being manufactured at BF Biosciences Limited’s new state-of-the-art European prefilled syringes line.

Pakistan faces a high prevalence of diabetes, with 8.9 million individuals undiagnosed and many struggling to manage the condition effectively. The launch of Sematide, following the introduction of Ferulin (Human Insulin), marks a significant step in BF Biosciences Limited’s commitment to combating diabetes in the country.

As the first biotech plant in Pakistan, the company has been dedicated to producing essential medicines for various therapeutic areas, including HCV, cancer, and cardiology, for over a decade.